Mizuno Y, et al. - In Japanese patients with early Parkinson disease (PD), researchers studied the long-term effectiveness and safety of selegiline as monotherapy. The sample consisted of patients with early PD (N = 134) who had previously completed the 12-week randomized, double-blind, placebo-controlled phase 3 trial of selegiline monotherapy. Dosing was titrated from 2.5 to 10 mg/d in increments of 2.5 mg/d for 2 weeks in the present study. The dosage was maintained at 10 mg/d up to week 56 from the seventh week. There were 91 patients who completed the 56-week study. Investigators found that the adverse drug reaction incidence rate was 44.3% and did not increase during the period of 10 mg selegiline administration. In this 56-week study, long-term monotherapy with selegiline (10 mg/d) was effective and well-tolerated in early PD patients. The total Unified Parkinson's Disease Rating Scale (UPDRS) score was significantly reduced from week 4 to week 56 with selegiline treatment, with peak effect seen at week 20.